RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics

— Robust pipeline of drugs against validated oncology targets —

— Focus on delivering Actinium-225, a powerful alpha-emitting radioisotope —

— Led by repeatedly successful management team —

October 14, 2020 08:00 AM Eastern Daylight Time

SAN DIEGO–(BUSINESS WIRE)–RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted radiopharmaceuticals. Co-lead investors venBio Partners and Versant Ventures were joined by Samsara BioCapital.